Mitigating the Effects of Gender Bias in Clinical Trials
January 31, 2022
Technion researchers have developed a technology that rectifies the effects of under-representation of women in clinical trials over machine learning models
The development of drugs and other medical treatments usually begins with basic research, followed by experiments in the laboratory, pre-clinical trials and, finally, clinical trials that confirm both the treatment’s efficacy in humans and its safety. Clinical trials are long and expensive processes that seal the fate of the proposed treatment – whether it will receive approval from the FDA or other authorities or be rejected. As a result, they play a central and critical role in the development of medical treatments.
A new article by researchers at the Henry and Marilyn Taub Faculty of Computer Science at the Technion – Israel Institute of Technology, in collaboration with Dr. Eric Horvitz of Microsoft Research, describes a specific bias that affects the implementation of these trials’ findings: underrepresentation of women in many clinical trials. The article, which was published in the Journal of the American Medical Informatics Association (JAMIA), depicts this bias and presents a special tool that can help compensate for this gender gap, thereby improving medical treatments for women.
According to Technion Ph.D. candidate Shunit Agmon, who conducted the research together with Technion alumna and visiting professor Dr. Kira Radinsky, “Nowadays, we know that different population groups react differently to a given treatment – in particular, women can have a different reaction than men to a treatment. For example, Zolpidem, a drug used to treat sleeping problems, clears more slowly in women and therefore it is important to prescribe a smaller dose for women than for men – which was discovered only after the drug was released to the market. The underrepresentation of women in clinical trials creates a problematic bias that harms the quality of women’s healthcare, including misdiagnosed diseases and adverse drug reactions.”
Gender bias in clinical trials is not new, and it has in fact worsened following traumatic events, including the Thalidomide affair – a drug that caused numerous birth defects when prescribed to pregnant women to alleviate morning sickness. That tragic episode, which took place in the early 1960s, led to a drastic decline in female participants in clinical trials.
In 1993, laws were passed in the United States that mandated the inclusion of women in these trials and the analysis of results with regards to gender. Yet, female underrepresentation remained a prevalent phenomenon, especially for trials that took place prior to 1993. Agmon points out that other population groups are also underrepresented, including certain age groups, ethnic groups, and other demographics. In some cases, there is also an underrepresentation of men, such as for diseases that are considered more “feminine,” such as fibromyalgia.
In recent years, machine learning models have been introduced to the world of medicine, aiming to improve medical diagnosis, treatment, and prevention. However, Agmon claims that “many of these models are based on biased trials and therefore they ‘inherit’ their biases, and in some cases even amplify them.”
The researchers explored this issue using machine learning tools, including natural language programming (NLP), and vector representation of words (word embeddings) – approaches that enable computers to “understand” texts. They used these methods on 16,772 articles from the PubMed database and allotted each one a “weight” based on the percentage of women in the clinical trials described in each article. This way, they developed an algorithmic tool that enables gender-sensitive use of clinical literature. This algorithm corrects the gender bias and improves the treatments’ suitability for female patients.
The algorithm succeeded in substantially improving predictions for women in various situations, including length of hospitalization, re-hospitalization within a month, and correlation between various diseases. Although the model focused on improving predictions for women, it also significantly improved overall clinical predictions (for men as well).
The researchers expect the JAMIA article to increase awareness of the problems of underrepresentation in research in general and in clinical trials in particular and will lead to additional solutions to improve the quality of personalized medicine.
For more than a century, the Technion – Israel Institute of Technology has pioneered in science and technology education and delivered world-changing impact. Proudly a global university, the Technion has long leveraged boundary-crossing collaborations to advance breakthrough research and technologies. Now with a presence in three countries, the Technion will prepare the next generation of global innovators. Technion people, ideas and inventions make immeasurable contributions to the world, innovating in fields from cancer research and sustainable energy to quantum computing and computer science to do good around the world.
The American Technion Society supports visionary education and world-changing impact through the Technion – Israel Institute of Technology. Based in New York City, we represent thousands of US donors, alumni and stakeholders who invest in the Technion’s growth and innovation to advance critical research and technologies that serve the State of Israel and the global good. Since 1940, our nationwide supporter network has funded new Technion scholarships, research, labs, and facilities that have helped deliver world-changing contributions and extend Technion education to campuses in three countries.